Document Detail

Impact of moderate dose of postoperative radiation on urinary continence and potency in patients with prostate cancer treated with nerve sparing prostatectomy.
MedLine Citation:
PMID:  8558674     Owner:  NLM     Status:  MEDLINE    
PURPOSE: We analyzed the impact on potency and urinary continence of moderate doses of radiation (45 to 54 Gy.) given postoperatively after nerve sparing prostatectomy. MATERIALS AND METHODS: Between 1983 and 1992, 294 of 762 prostate cancer patients were selected to undergo nerve sparing prostatectomy. Subjective patient reports regarding potency and urinary continence status were obtained preoperatively, 1 year postoperatively or 1 year after completion of radiation. RESULTS: Of the 294 patients 105 received postoperative radiotherapy (45 to 54 Gy.) to the prostatic bed. There were patients with more advanced stages of disease in the irradiated group, including 89% with stages C and D1 (pT3N0 and pT1 to 3, N1 to 3), compared to 14% with stages C and D1 (pT3N0 and pT1 to 3, N1 to 3) in the nonirradiated group (p < 0.001). No difference in urinary continence was noted in the irradiated (94%) compared to the nonirradiated group (92%, p = 0.64). Of the patients who underwent bilateral nerve sparing prostatectomy 44% who received and 48% who did not receive radiation had recovered potency at 1 year (p = 0.76). Of those who underwent unilateral nerve sparing prostatectomy 10% who received and 33% who did not receive radiation had recovered potency at 1 year (p = 0.14). Using multivariate analysis patient age younger than 63 years and bilateral versus unilateral nerve sparing procedures were significant predictors of potency. CONCLUSIONS: Our retrospective study suggests that at 1 year after treatment moderate doses of postoperative radiotherapy did not have a significant impact on the recovery of urinary continence and potency after nerve sparing prostatectomy. However, longer followup is required to determine the impact of this radiation protocol on long-term preservation of potency after nerve sparing prostatectomy.
S C Formenti; G Lieskovsky; A R Simoneau; D Skinner; S Groshen; S C Chen; Z Petrovich
Related Documents :
10552144 - Lower-energy thermotherapy in the treatment of benign prostatic hyperplasia: long-term ...
14532784 - Health related quality of life patterns in patients treated with interstitial prostate ...
9855124 - Urologic morbidity and its influence on global satisfaction with treatment outcome afte...
9255294 - Clinical outcome at 3 months after transurethral vaporization of prostate for benign pr...
23271674 - Immediate versus deferred empirical antifungal (idea) therapy in high-risk patients wit...
638424 - Closure of gastrojejunostomy for the relief of post-vagotomy symptoms.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  The Journal of urology     Volume:  155     ISSN:  0022-5347     ISO Abbreviation:  J. Urol.     Publication Date:  1996 Feb 
Date Detail:
Created Date:  1996-02-23     Completed Date:  1996-02-23     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0376374     Medline TA:  J Urol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  616-9     Citation Subset:  AIM; IM    
Department of Radiation Oncology, University of Southern California School of Medicine, Los Angeles, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Combined Modality Therapy
Erectile Dysfunction / epidemiology,  etiology
Middle Aged
Multivariate Analysis
Postoperative Care
Prostate / innervation
Prostatectomy / adverse effects,  methods*
Prostatic Neoplasms / radiotherapy*,  surgery*
Radiotherapy / adverse effects
Radiotherapy Dosage
Retrospective Studies
Urinary Incontinence / epidemiology,  etiology

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Radical perineal prostatectomy without pelvic lymphadenectomy: selection criteria and early results.
Next Document:  Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate spec...